# FT516 and IL2 With Enoblituzumab for Ovarian Cancer

> **NCT04630769** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 3 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Adenocarcinoma
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** IP FT516
- **DRUG:** Enoblituzumab
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT04630769
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-02
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630769, "FT516 and IL2 With Enoblituzumab for Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04630769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*